SEQUENOM, Inc. Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Sequenom, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Contents

• 1 List of Tables
  • 1.2 List of Figures
• 2 Company Snapshot
  • 2.1 Key Information
  • 2.2 Company Overview
  • 2.3 Financial Performance
  • 2.4 Industry Outlook - In Vitro Diagnostics
• 3 Business Description
  • 3.1 Business Overview
  • 3.2 Major Products and Services
    • 3.2.1 Overview
• 4 Competitors
• 5 Key Employees
• 6 Key Employee Biographies
• 7 Company Statement
• 8 Locations And Subsidiaries
  • 8.1 Head Office
  • 8.2 Other Locations & Subsidiaries
• 9 Recent Developments
  • 9.1 Strategy And Business Planning
    • 9.1.1 Jan 30, 2008: Sequenom Conducts Multi-Center Study With NAFTNet
  • 9.2 Financial Announcements
    • 9.2.1 Jul 30, 2008: Sequenom Reports 2Q 2008 Results
    • 9.2.2 Apr 30, 2008: Sequenom Declares Q1 2008 Results
    • 9.2.3 Apr 14, 2008: Sequenom To Declare Q1 2008 Results
    • 9.2.4 Feb 20, 2008: Sequenom Declares Q4 2007 Results
    • 9.2.5 Oct 31, 2007: Sequenom Declares Q3 2007 Results
    • 9.2.6 Aug 06, 2007: Sequenom Declares Q2 2007 Results
    • 9.2.7 May 07, 2007: Sequenom Declares Q1 2007 Results
    • 9.2.8 Mar 07, 2007: Sequenom Declares Q4 2006 Results
    • 9.2.9 Nov 02, 2006: Sequenom Declares Q3 2006 Results
  • 9.3 Research And Development
    • 9.3.1 Jan 30, 2008: Sequenom Conducts Multi-Center Study With NAFTNet
  • 9.4 Corporate Communications
    • 9.4.1 Nov 01, 2007: Sequenom Appoints New Board Member
    • 9.4.2 Jul 09, 2007: Sequenom Elects New Board Member
    • 9.4.3 Jun 26, 2007: Sequenom Elects New Board Member
    • 9.4.4 Feb 20, 2007: Sequenom Appoints New CFO
  • 9.5 Product News
    • 9.5.1 Jun 04, 2008: SEQureDx Technology On The MassARRAY Platform
    • 9.5.2 May 28, 2008: Johns Hopkins University Purchases Sequenom MassARRAY Platform
    • 9.5.3 Mar 12, 2008: Sequenom Announces Multiple MassARRAY Systems Sales In China
    • 9.5.4 Feb 20, 2008: Sequenom Announces Key Milestone In Development Of Noninvasive Prenatal Downs Syndrome Test
    • 9.5.5 Jan 30, 2008: Sequenom and NAFTNet to Conduct Fetal Rhesus D Study in Collaboration with Baylor College of Medicine
    • 9.5.6 Jan 30, 2008: Sequenom And NAFTNet To Conduct Fetal Rhesus D Study In Collaboration With Baylor College Of Medicine
    • 9.5.7 Jan 23, 2008: Sequenom to Begin Clinical Assessment of Noninvasive Screening Technology for Down Syndrome
    • 9.5.8 Jan 23, 2008: Sequenom To Begin Clinical Assessment Of Noninvasive Screening Technology For Downs Syndrome
    • 9.5.9 Jan 08, 2008: QIAGEN And Sequenom Enter Into A Collaboration Targeting Prenatal Diagnostics
    • 9.5.10 Dec 27, 2007: Sequenom Announces New York State Approval Of A Noninvasive Prenatal Test
    • 9.5.11 Jun 28, 2007: Lenetix Reports Submission Of Clinical Data To New York State Authorities For The Commercial Launch Of Non-Invasive Prenatal Rhesus D Incompatibility Test
    • 9.5.12 May 08, 2007: Sequenom Announces Positive Clinical Data And Performance For The Fetal Rhesus D Genotyping Assay
    • 9.5.13 Feb 09, 2007: New Data Supports A Non-Invasive Approach To Routine Prenatal Genetic Testing
    • 9.5.14 Jan 29, 2007: Sequenom And Lenetix Enter Agreement To Develop And Commercialize Rhesus D Prenatal Diagnostic
    • 9.5.15 Oct 20, 2005: SEQureDx Technology On The MassARRAY Platform
  • 9.6 Product Approvals
    • 9.6.1 Dec 27, 2007: Sequenom Announces New York State Approval Of A Noninvasive Prenatal Test
  • 9.7 Clinical Trials
    • 9.7.1 Jun 04, 2008: SEQureDx Technology On The MassARRAY Platform
    • 9.7.2 Feb 20, 2008: Sequenom Announces Key Milestone In Development Of Noninvasive Prenatal Downs Syndrome Test
    • 9.7.3 Jan 30, 2008: Sequenom and NAFTNet to Conduct Fetal Rhesus D Study in Collaboration with Baylor College of Medicine
    • 9.7.4 Jan 30, 2008: Sequenom And NAFTNet To Conduct Fetal Rhesus D Study In Collaboration With Baylor College Of Medicine
    • 9.7.5 Jan 23, 2008: Sequenom To Begin Clinical Assessment Of Noninvasive Screening Technology For Downs Syndrome
    • 9.7.6 Jan 23, 2008: Sequenom to Begin Clinical Assessment of Noninvasive Screening Technology for Down Syndrome
    • 9.7.7 Jun 28, 2007: Lenetix Reports Submission Of Clinical Data To New York State Authorities For The Commercial Launch Of Non-Invasive Prenatal Rhesus D Incompatibility Test
    • 9.7.8 May 08, 2007: Sequenom Announces Positive Clinical Data And Performance For The Fetal Rhesus D Genotyping Assay
• 10 Sequenom, Inc. Pipeline Products
  • 10.1 Sequenom, Inc. Product Pipeline Analysis
    • 10.1.1 Sequenom, Inc. Pipeline Products By Equipment Type
    • 10.1.2 Sequenom, Inc. Pipeline Products By Development Stage
    • 10.1.3 Sequenom, Inc. Pipeline Products By Therapy Area
    • 10.1.4 Sequenom, Inc. Pipeline Products By Clinical Trials
    • 10.1.5 Sequenom, Inc. Pipeline Products By News Summary
  • 10.2 Preanalytical solution-Fetal DNA analysis
    • 10.2.1 Product Description
    • 10.2.2 Product Status
    • 10.2.3 Product Milestone
  • 10.3 MassARRAY System Enhancements
    • 10.3.1 Product Description
    • 10.3.2 Product Status
    • 10.3.3 Product Milestone
    • 10.3.4 Product Patent Details
  • 10.4 Trisomy 21 test
    • 10.4.1 Product Description
    • 10.4.2 Product Status
    • 10.4.3 Product Milestone
  • 10.5 Noninvasive prenatal test for Rhesus D incompatibility
    • 10.5.1 Product Description
    • 10.5.2 Product Status
    • 10.5.3 Clinical Trials
    • 10.5.4 Product Milestone
  • 10.6 SEQureDx Technology on the MassARRAY Platform
    • 10.6.1 Product Description
    • 10.6.2 Product Status
    • 10.6.3 Clinical Trials
    • 10.6.4 Product Milestone
  • 10.7 Third-generation iPLEX genotyping assay
    • 10.7.1 Product Description
    • 10.7.2 Product Status
  • 10.8 Closed Tube Assay
    • 10.8.1 Product Description
    • 10.8.2 Product Status
• 11 Appendix
  • 11.1 Methodology
    • 11.1.1 Coverage
    • 11.1.2 Secondary Research
    • 11.1.3 Primary Research
    • 11.1.4 Expert Panel Validation
  • 11.2 Contact Us
  • 11.3 About Global Markets Direct
  • 11.4 Disclaimer
• 1 List of Tables
  • Table 1: SEQUENOM, Inc.,Key Facts
  • Table 2: SEQUENOM, Inc., Key Employees,
  • Table 3: SEQUENOM, Inc., Other Locations
  • Table 4: SEQUENOM, Inc., Subsidiaries
  • Table 5: Sequenom, Inc. Pipeline Products by Equipment Type
  • Table 6: Sequenom, Inc. Pipeline Products By Development Stage
  • Table 7: Sequenom, Inc. Pipeline Products By Therapy Area
  • Table 8: Sequenom, Inc. Pipeline Products By Clinical Trials
  • Table 9: Sequenom, Inc. Pipeline Products By News Summaries
  • 1.2 List of Figures
  • Figure 1: Sequenom, Inc. Pipeline Products By Development Stage
  • Figure 2: Sequenom, Inc. Pipeline Products By News Summary
  • Figure 3: Global Markets Direct Methodology